Playa Hotels & Resorts (NASDAQ:PLYA) Surprises With Q4 Sales
  • February 25, 2025

Playa Hotels & Resorts (NASDAQ:PLYA) Surprises With Q4 Sales

Hospitality company Playa Hotels & Resorts (NASDAQ:PLYA) reported Q4 CY2024 results topping the market’s revenue expectations, but sales fell by 9.7% year on year to $218.9 million. Its non-GAAP profit of $0.08 per share was significantly above analysts’ consensus estimates.

Jazz Pharmaceuticals (NASDAQ:JAZZ) Surprises With Q4 Sales
  • February 25, 2025

Jazz Pharmaceuticals (NASDAQ:JAZZ) Surprises With Q4 Sales

Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) beat Wall Street’s revenue expectations in Q4 CY2024, with sales up 7.5% year on year to $1.09 billion. On the other hand, the company’s full-year revenue guidance of $4.28 billion at the midpoint came in 1.5% below analysts’ estimates. Its non-GAAP profit of $6.60 per share was 13.6% above analysts’ consensus estimates.

Supernus Pharmaceuticals (NASDAQ:SUPN) Delivers Strong Q4 Numbers
  • February 25, 2025

Supernus Pharmaceuticals (NASDAQ:SUPN) Delivers Strong Q4 Numbers

Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) reported Q4 CY2024 results beating Wall Street’s revenue expectations, with sales up 6% year on year to $174.2 million. On the other hand, the company’s full-year revenue guidance of $615 million at the midpoint came in 1.2% below analysts’ estimates. Its GAAP profit of $0.27 per share was significantly above analysts’ consensus estimates.